YJZ5118
YJZ5118 is a selective CDK12/CDK13 inhibitor with IC50 values of 39.5 nM and 26.4 nM. YJZ5118 suppresses transcription of DNA damage response genes and induces DNA damage in tumor cells. YJZ5118 inhibits proliferation and triggers apoptosis. YJZ5118 inhibits RNA polymerase II Ser2 phosphorylation and increases Akt pathway activity. YJZ5118 exhibits synergistic effects with Akt inhibitors. YJZ5118 can be used for the research of cancer, such as prostate cancer.
For research use only. We do not sell to patients.
- CAS No.: 3031861-18-1
- Formula: C36H44N8O2
- Molecular Weight:620.79
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
RNA Polymerase |
CDK12 39.5 nM (IC50) |
CDK13 26.4 nM (IC50) |
In Vitro
YJZ5118 is a potent, selective inhibitor of recombinant CDK12/Cyclin K and CDK13/Cyclin K with IC50 values of 39.5 nM and 26.4 nM, respectively, and over 100-fold selectivity relative to most other CDK family members[1].
YJZ5118 (0.1 μM; 2 h) acts as an irreversible inhibitor in VCaP prostate cancer cells, maintaining suppression of RNA polymerase II Ser2 phosphorylation, DDR gene expression, and antiproliferative activity after compound washout[1].
YJZ5118 (5 days) potently inhibits VCaP prostate cancer cell proliferation with an IC50 of 23.7 nM, and shows preferential activity against multiple cancer cell lines including prostate, breast, and Ewing's sarcoma cells, while normal/non-neoplastic cells are less sensitive[1].
YJZ5118 (20-100 nM; 1-48 h) inhibits RNA polymerase II Ser2 phosphorylation, suppresses transcription of long DDR genes, induces DNA damage, and triggers apoptosis in VCaP prostate cancer cells at concentrations as low as 100 nM[1].
YJZ5118 (10-100 nM; 24 h) dose-dependently activates the Akt pathway in VCaP prostate cancer cells, and exhibits synergistic antiproliferative effects with multiple Akt inhibitors in 22RV1 prostate cancer cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:VCaP
cells -
Concentration:20, 50, 100 nM
-
Incubation Time:1, 2, 4, 6, 8, 15, 24 h
-
Result:Reduced RNA polymerase II Ser2 phosphorylation levels.
-
Cell Line:VCaP
cells -
Concentration:10, 20, 50, 100 nM
-
Incubation Time:24 h
-
Result:Increased p-AKT and pPRAS40 levels.
Increased cPARP and γH2Ax levels.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG; CB17SCID (female, 6-8 weeks old, orthotopic VCaP CRPC xenograft model)[1]
-
Dosage:0.5 mg/kg; 1.5 mg/kg
-
Administration:i.p.; daily; 27 days
-
Result:Significantly reduced tumor volume compared to vehicle control.
Significantly lowered tumor weight compared to vehicle controls.
Inhibited phosphorylation of RNA polymerase II at Serine 2.
Increased levels of pAkt (S473) and pPRAS40 in tumors.
Reduced mRNA expression of DDR genes (ATM, ATR, BRCA1).
Did not alter CDK12 gene expression.
Increased pAkt levels and enhanced apoptosis in tumor sections (histological analysis).
Caused no significant changes in animal body weights.
Chemical Information
-
CAS No. 3031861-18-1
-
Molecular Weight 620.79
-
Formula C36H44N8O2
-
SMILES
C=CC(NC1=CC(N(C(NCC2=CC=CC=C2)=O)[C@H]3CC[C@@H](CC3)NC4=NC=C(C=C4)C#N)=CC=C1N5CCC(CC5)N(C)C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)